SELECT PUBLICATIONS
Allegra C, Sargent DJ. Adjuvant therapy for colon cancer — The pace quickens. N Engl J
Med 2005;352:2746-8. No abstract available
Andre T et al. Oxaliplatin, fluorouracil, and leucovorin as adjuvant treatment for colon
cancer. N Engl J Med 2004;350:2343-51. Abstract
Dolinsky CM et al. Evidence for improved pathologic complete response (PCR) rate after
preoperative chemoradiotherapy with 5-FU/oxaliplatin (5FU/OX) for rectal cancer. Proc
ASCO 2006;Abstract 3567.
Haller DG et al. Tolerability of fluoropyrimidines appears to differ by region. Proc ASCO
2006;Abstract 3514.
Hedrick E et al. Safety of bevacizumab plus chemotherapy as first-line treatment of
patients with metastatic colorectal cancer: Updated results from a large observational
registry in the US (BRiTE). Proc ASCO 2006;Abstract 3536.
Hoff PM et al. Comparison of oral capecitabine versus intravenous fluorouracil plus
leucovorin as first-line treatment in 605 patients with metastatic colorectal cancer:
Results of a randomized phase III study. J Clin Oncol 2001;19:2282-92. Abstract
Hurwitz H et al. Bevacizumab (a monoclonal antibody to vascular endothelial growth
factor) prolongs survival in first-line colorectal cancer (CRC): Results of a phase
III trial of bevacizumab in combination with bolus IFL (irinotecan, 5-fluorouracil,
leucovorin) as first-line therapy in subjects with metastatic CRC. Proc ASCO
2003;Abstract 3646.
International Multicentre Pooled Analysis of Colon Cancer Trials (IMPACT) Investigators.
Efficacy of adjuvant fluorouracil and folinic acid in colon cancer. Lancet 1995;345:939-44. Abstract
Rosenthal DI. ECOG 1297: A phase I study of preoperative radiation therapy (RT)
with concurrent protracted continuous infusion 5-FU and dose escalating oxaliplatin
followed by surgery, adjuvant 5-FU, and leucovorin for locally advanced (T3/4) rectal
adenocarcinoma. Proc ASCO 2003;Abstract 1094.
Ryan DP et al. Phase I/II study of preoperative oxaliplatin, fluorouracil, and external-beam
radiation therapy in patients with locally advanced rectal cancer: Cancer and
Leukemia Group B 89901. J Clin Oncol 2006;24:2557-62. Abstract
Saltz LB et al. Irinotecan plus fluorouracil/leucovorin (IFL) versus fluorouracil/leucovorin
alone (FL) in stage III colon cancer (Intergroup trial CALGB C89803). Proc ASCO
2004;Abstract 3500.
Sauer R et al. Preoperative versus postoperative chemoradiotherapy for rectal cancer.
N Engl J Med 2004;351:1731-40. Abstract
Schmoll HJ et al. Final safety findings from a randomized phase III trial of capecitabine
+ oxaliplatin (XELOX) vs bolus 5-FU/LV as adjuvant therapy for patients with stage
III colon cancer. Proc ASCO 2006;Abstract 3569.
Schmoll HJ et al. Early safety findings from a phase III trial of capecitabine plus oxaliplatin
(XELOX) vs bolus 5-FU/LV as adjuvant therapy for patients with stage III colon
cancer. Proc ASCO 2005;Abstract 3523.
Van Cutsem E et al. Oral capecitabine compared with intravenous fluorouracil plus
leucovorin in patients with metastatic colorectal cancer: Results of a large phase III
study. J Clin Oncol 2001;19:4097-106. Abstract
